Posted by Michael Wonder on 23 May 2021
Prescription medicines: applications under evaluation (May 2021 update)
21 May 2021 - The TGA has updated its list of applications for new medicines or new uses for existing medicines that are currently under evaluation, including a submission from Biogen for aducanumab.
The list increased by 6 in April:
- Patiromer sorbitex calcium (Veltassa) - new indication
- Ertugliflozin pidolate (Steglatro) - new indication
- Ertugliflozin pidolate with metformin hydrochloride (Segluromet) - new indication
- Ertugliflozin pidolate with sitagliptin phosphate monohydrate (Steglujan) - new indication
- Risankizumab (Skyrizi) - new indication
- Aducanumab (Aduhelm) - new medicine
